EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Study of lncRNAs expression profile in the response to biological drugs in Psoriatic Arthritis: MEG3 could be a potential genomic biomarker of therapy efficacy

Giada De Benedittis, Arianna D'Antonio, Andrea Latini, Chiara Morgante, Paola Conigliaro, Paola Triggianese, Alberto Bergamini, Giuseppe Novelli, Cinzia Ciccacci, Maria Sole Chimenti, Paola Borgiani

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112239 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Giada De Benedittis und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine and Prevention, Section of Genetics, University of Rome "Tor Vergata", 00133 Rome, Italy. Hauptthemen laut MEDLINE: RNA, Long Noncoding, Arthritis, Psoriatic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We aimed to identify an expression profile of lncRNAs potentially related to treatment response in Psoriatic arthritis (PsA) patients, to be used as potential genomic biomarkers predictors of drug treatment effectiveness. In addition, we evaluated a possible association between lncRNAs genetic variants and the response to therapy using the clinical parameter of Disease Activity Index. For the expression study, we collected 48 treated PsA patients, monitoring the treatment response for 12 months. We initially used PCR Array and, then, we validated the results with qRT-PCR. We also retrospectively genotyped 163 treated PsA patients. Firstly, we observed a significant difference in the expression level between Responder and non-Responder patients, of 4 lncRNAs in the group of PsA patients treated with TNFi and of 3 lncRNAs in the group of patients treated with IL17i. Then, we confirmed a significant decrease of MEG3 expression in non-Responder patients compared to Responders, also considering separately the single groups of patients treated with TNFi and IL17i. In addition, our results seem to highlight a potential dose-dependent effect of rs941576 (MEG3) variant allele on Disease Activity Index. Our study suggests a possible role of the lncRNA MEG3 in the treatment response to biological drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, Long NoncodingArthritis, PsoriaticHumansMaleFemaleMiddle AgedAdultTreatment OutcomeRetrospective StudiesBiomarkersPolymorphism, Single NucleotideInterleukin-17Biological ProductsAntirheumatic Agents

Stichwörter der Autor:innen

MEG3Personalised medicinePsoriatic arthritisTreatment responselncRNAs

Substanzen

RNA, Long NoncodingMEG3 non-coding RNA, humanBiomarkersInterleukin-17Biological ProductsAntirheumatic Agents

Autor:innen und Institutionen

  • Department of Biomedicine and Prevention, Section of Genetics, University of Rome "Tor Vergata", 00133 Rome, Italy.
  • Rheumatology, Allergology and Clinical Immunology, Department of System Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy.
  • Department of Biomedicine and Prevention, Section of Genetics, University of Rome "Tor Vergata", 00133 Rome, Italy. Electronic address: a.latini@med.uniroma2.it.
  • Department of Biomedicine and Prevention, Section of Genetics, University of Rome "Tor Vergata", 00133 Rome, Italy; School of Medicine, Department of Pharmacology, University of Nevada, 89557 Reno, USA; IRCCS NEUROMED,…
  • UniCamillus-Saint Camillus International University of Health Sciences, 00131 Rome, Italy.

Zitieren

APA

De Benedittis, G., D'Antonio, A., Latini, A., Morgante, C., Conigliaro, P., Triggianese, P., Bergamini, A., Novelli, G., Ciccacci, C., Chimenti, M. S., & Borgiani, P. (2024). Study of lncRNAs expression profile in the response to biological drugs in Psoriatic Arthritis: MEG3 could be a potential genomic biomarker of therapy efficacy. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112239

Vancouver

De Benedittis G, D'Antonio A, Latini A, Morgante C, Conigliaro P, Triggianese P, et al. Study of lncRNAs expression profile in the response to biological drugs in Psoriatic Arthritis: MEG3 could be a potential genomic biomarker of therapy efficacy. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112239

BibTeX
@article{DeBenedittis2024,
  author = {De Benedittis, Giada and D'Antonio, Arianna and Latini, Andrea and Morgante, Chiara and Conigliaro, Paola and Triggianese, Paola and Bergamini, Alberto and Novelli, Giuseppe and Ciccacci, Cinzia and Chimenti, Maria Sole and Borgiani, Paola},
  title = {Study of lncRNAs expression profile in the response to biological drugs in Psoriatic Arthritis: MEG3 could be a potential genomic biomarker of therapy efficacy},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112239}
}
Kostenlos starten →